Quick Answer
LIGAND PHARMACEUTICALS INC reported Total Revenue of $268.09 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $268.09M | +60.4% |
| 2024 | $167.13M | +27.3% |
| 2023 | $131.31M | -33.1% |
| 2022 | $196.25M | -18.8% |
| 2021 | $241.54M | +47.7% |
| 2020 | $163.56M | +36.0% |
| 2019 | $120.28M | -52.2% |
| 2018 | $251.45M | +78.2% |
| 2017 | $141.10M | +29.5% |
| 2016 | $108.97M | +51.5% |
| 2015 | $71.91M | +11.4% |
| 2014 | $64.54M | +31.8% |
| 2013 | $48.97M | +56.0% |
| 2012 | $31.39M | +4.5% |
| 2011 | $30.04M | +27.6% |
| 2010 | $23.54M | -39.6% |
| 2009 | $38.94M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.46M | +122.8% | +142.4% |
| June 30, 2025 | $47.63M | +14.7% | +5.1% |
| March 31, 2025 | $45.33M | +46.3% | -12.5% |
| September 30, 2024 | $51.81M | +57.6% | +24.8% |
| June 30, 2024 | $41.53M | +57.5% | +34.1% |
| March 31, 2024 | $30.98M | -29.6% | -5.8% |
| September 30, 2023 | $32.87M | -44.5% | +24.7% |
| June 30, 2023 | $26.37M | -47.4% | -40.0% |
- LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Total Revenue compared to the prior fiscal year.
- Over the 2009–2025 period, LIGAND PHARMACEUTICALS INC’s total revenue has grown by 588.5% (from $38.94 million to $268.09 million).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: